Gelonghui, March 13, 丨 Yihe Holdings (01662.HK) announced that the APEL Biomedical Technology Innovation and Transformation Business Laboratory located at the Hong Kong Science Park (“Hong Kong Science Park”) will officially open on March 13, 2024. The commercial laboratory was founded by Absolute Pure Enviro Sci Limited, an indirect non-wholly-owned subsidiary of the company.
The establishment and opening of a commercial laboratory is the first phase of APEL's strategic plan to establish a laboratory in the Hong Kong Science Park. The Group plans to use the commercial laboratory as a hub for integrating biomedical and new materials business, R&D, application transformation and commercialization of R&D results.
The Board believes that the establishment of a commercial laboratory will provide the Group with an opportunity to enter the biomedical and new materials technology markets. The Group believes that a sustainable development strategy is an important driving force for continued development. The Group expects to use commercial laboratory resources and expertise to diversify its business and enhance long-term competitiveness. Furthermore, the Group looks forward to cooperating with a new generation of researchers to jointly contribute to Hong Kong's innovative industry and inject momentum into the long-term development of Hong Kong's re-industrialization.
After establishing a commercial laboratory, the Group will strive to diversify its business and enter the fields of biomedicine and new materials technology. The Group has also been actively seeking opportunities to commercialize high-quality R&D projects related to breakthrough technologies developed by the University of Hong Kong.
The board of directors believes that the above strategic plan will benefit the company's shareholders and conform to the long-term development trends of the market and industry. The successful launch of new products for major emerging customers helped the company record good sales and revenue growth. Looking forward to the future, the Group will continue to be engaged in the main business in the construction industry, and new business initiatives in the biomedicine and new materials technology fields are expected to drive the Group's future growth and strengthen its business model in the long term through creativity and innovation.